Meet Mia | Pradaxa® Patient Profiles | Boehringer Ingelheim

Meet Mia

  • 73 years old
  • Enjoys cooking—and walking
    to the market every day to gather
    fresh ingredients!
  • Taking rivaroxaban for nonvalvular atrial fibrillation
    (NVAF) but is concerned over her recent experience
    with bleeding

How will you help Mia?

Scroll to
find out

Mia wants to reduce her risk of bleeding

Significantly lower risk of major bleeding in real-world observational
analyses of 187,121 patients taking Pradaxa
® vs rivaroxaban1-3

‘Data indicating significantly lower risk of major bleeding when taking Pradaxa vs Rivaroxaban’

BD, both doses; ECH, extracranial haemorrhage; HD, high dose; LD, low dose.
*Statistically nonsignificant difference.
Chan, n=9,837; Hernandez, n=17,505; Graham, N=118,891; Lip, n=9,314; Noseworthy, n=31,574. Not head-to-head studies.
In the EU, the licensed doses for Pradaxa® are 150 mg BID and 110 mg BID for the prevention of stroke and systemic embolism in adult patients with NVAF.
In the United States, the licensed doses for Pradaxa® are 150 mg BID and 75 mg BID for the prevention of stroke and systemic embolism in adult patients with NVAF.

Mia will thank you for switching her
to Pradaxa®

Superior safety outcomes with Pradaxa® 150 mg vs rivaroxaban 20 mg,
as measured in an independent, real-world, observational analysis
of 18,000+ patients
2
‘From independent analysis of 18,000+ patients, Pradaxa has superior safety outcomes vs Rivaroxaban’

Not a head-to-head study.
Other doses studied but not reported here were Pradaxa® 75 mg and rivaroxaban 15 mg and 10 mg.
In the EU, the licensed doses for Pradaxa® are 150 mg BID and 110 mg BID for the prevention of stroke and systemic embolism in adult patients with NVAF.
In the United States, the licensed doses for Pradaxa® are 150 mg BID and 75 mg BID for the prevention of stroke and systemic embolism in adult patients with NVAF.

How to switch Mia from rivaroxaban
to Pradaxa®

According to updated European Heart Rhythm Association guidelines, the
new NOAC may be initiated at the time of the next dose*
4
‘European Heart Rhythm Association guidelines say new NOAC may be initiated at time of next dose’

*Exceptions to this recommendation include circumstances where higher than therapeutic plasma concentrations are expected (eg, in patients with impaired renal function). In these
cases, a longer interval between previous and next dose may be necessary.

Life Happens

If Mia ever needs it, Praxbind® provides the reassurance of specific, immediate, and complete reversal of Pradaxa®

  • Dual indication—for life-threatening or uncontrolled bleeding and emergency surgery/urgent procedures5

  • Specific binding allows for immediate and complete reversal of Pradaxa® with no procoagulant effects5

  • Easy to use—1 ready-to-use dose for ALL Pradaxa® patients5

  • Widely available—8,300+ sites in 48 countries6

  • References:
  • 1. Bai Y et al. Stroke. 2017;48(4):970-976.
  • 2. Hernandez I et al. Am J Cardiovasc Drugs. 2017;17(1):37-47.
  • 3. Lip GYH et al. Thromb Haemost. 2016;116(5):975-986.
  • 4. Heidbuchel H et al. Europace. 2015;17(10):1467-1507.
  • 5. Praxbind® (idarucizumab) Summary of Product Characteristics. 2018.
  • 6. Data on file. Boehringer Ingelheim.